89bio

Understanding the science behind liver diseases, such as metabolic dysfunction-associated steatohepatitis (MASH) and metabolic-associated steatotic liver disease (MASLD), can be difficult – especially with the many acronyms we use in this disease state. At 89bio, we recognize education is a crucial component in supporting patients with liver disease. Learn more about our mission and commitment to patients with different cardiometabolic diseases: https://lnkd.in/grqTsDmY

Our CEO Rohan Palekar was recently featured in the prestigious annual “Scrip Asks” series, where industry leaders share their visions for the future. Amid a growing prevalence rate of #MASH, Rohan shares our team’s excitement about the potential for more therapeutic options for cardiometabolic diseases and progress in the adoption of non-invasive tests that better support the unique treatment needs of this large and growing patient population. Read the full feature here: https://lnkd.in/dSyX8Mmu

📍 The 89bio team is participating in the Leerink Partners Global Healthcare Conference in Miami, FL from March 10-12. If you are attending, be sure to say hello to our team. Details here: https://lnkd.in/gYKYAESH #Biotech #LiverDisease 

Today, 89bio reported their Q4 and full year financial earnings along with business updates. We are thrilled to share our progress last year and we thank our team of 89ers for all their hard work and dedication in 2024. Read our release to learn more: https://lnkd.in/gW_WvDiR #The89Way #Biotech #LiverDisease

#DYK the prevalence of metabolic dysfunction-associated steatohepatitis (MASH) continues to steadily increase globally? This statistic drives our team at 89bio to develop therapeutic options for a diverse and growing patient population in #MASH. For those with MASH, the major risk is the progression to fibrosis, which can cause cirrhosis of the liver. Therefore, the primary treatment goal in MASH is reducing liver fibrosis. Learn how 89bio is committed to developing innovative therapies for the treatment of MASH with advanced fibrosis: https://lnkd.in/grqTsDmY   #CardioMetabolicDiseases #Innovation 

Grow with us! We’re currently seeking passionate visionaries who are eager to deliver therapeutics for #CardioMetabolicDiseases and improve outcomes for patients! Learn about the #89way and if our dynamic group of 89ers sounds right for you. Consider joining our team: https://lnkd.in/gnP5i8-n #Lifeat89bio #BioPharma #Recruitment #JobOpening #NewJobs

February 11 was International Day of Women and Girls in Science, a day of celebration that our team at 89bio proudly supports each year. Following this important day, we’re spotlighting our Chief Regulatory and Quality Officer, Teresa Perney, PhD.   Having joined our team only 5 months ago, Dr. Perney has already demonstrated her 20+ years of experience as a passionate, dedicated and talented 89er. Thank you, Teresa for your unwavering drive to deliver innovative therapies for #CardioMetabolicDiseases.   Read about our values to see how Teresa embodies the #89way: https://lnkd.in/gtY6DB6v   #WomeninSTEM #WomeninScience 

How much do you know about fibroblast growth factor 21, known as FGF21? Often referred to as a master metabolic regulator, FGF21 is an endogenous hormone, meaning it is produced by your body – specifically your liver. Importantly, FGF21 has broad metabolic effects and therefore has the potential to address underlying metabolic issues that drive #CardioMetabolic diseases. Learn more about the science and how our FGF21 candidate shows promise in #MASH and #SHTG: https://lnkd.in/gCZYq9u

Metabolic dysfunction-associated steatohepatitis, or MASH, is often called a “silent disease,” but with a steadily increasing global prevalence rate, our team at 89bio is committed to making noise about the disease and its consequences.   Although the disease often advances quietly throughout the body, if left unchecked MASH can lead to serious complications such as cirrhosis and liver cancer. Learn about 89bio’s commitment to advancing research and progressing our innovative treatment for patients with cardiometabolic diseases, like MASH: https://lnkd.in/gCZYq9u #CardioMetabolicDiseases #MASH #Innovation

Join our growing team at 89bio! Our team encompasses a dynamic group of experts who embrace an entrepreneurial spirit, seek out innovative science and are driven to bring change to patients. If this sounds like you, learn more about #the89way and see if you may fit into one of our open roles: https://lnkd.in/gnP5i8-n #Lifeat89bio #BioPharma #Recruitment #JobOpening #NewJobs